Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials

F. Cremonini, S. Delgado-Aros, Michael Camilleri

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five percent of the patients experienced diarrhoea-predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95% confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalNeurogastroenterology and Motility
Volume15
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Irritable Bowel Syndrome
Meta-Analysis
Randomized Controlled Trials
Placebos
Pain
Confidence Intervals
alosetron
Numbers Needed To Treat
Constipation
Diarrhea
Odds Ratio
Therapeutics

Keywords

  • 5-HT antagonists
  • Alosetron
  • Irritable bowel syndrome
  • Meta-analysis
  • Serotonin

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

Efficacy of alosetron in irritable bowel syndrome : A meta-analysis of randomized controlled trials. / Cremonini, F.; Delgado-Aros, S.; Camilleri, Michael.

In: Neurogastroenterology and Motility, Vol. 15, No. 1, 02.2003, p. 79-86.

Research output: Contribution to journalArticle

@article{11e82d4fc1dc48d5b491c9a771a1b67a,
title = "Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials",
abstract = "The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five percent of the patients experienced diarrhoea-predominant IBS and 93{\%} were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95{\%} confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95{\%} CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.",
keywords = "5-HT antagonists, Alosetron, Irritable bowel syndrome, Meta-analysis, Serotonin",
author = "F. Cremonini and S. Delgado-Aros and Michael Camilleri",
year = "2003",
month = "2",
doi = "10.1046/j.1365-2982.2003.00389.x",
language = "English (US)",
volume = "15",
pages = "79--86",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy of alosetron in irritable bowel syndrome

T2 - A meta-analysis of randomized controlled trials

AU - Cremonini, F.

AU - Delgado-Aros, S.

AU - Camilleri, Michael

PY - 2003/2

Y1 - 2003/2

N2 - The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five percent of the patients experienced diarrhoea-predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95% confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.

AB - The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five percent of the patients experienced diarrhoea-predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95% confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.

KW - 5-HT antagonists

KW - Alosetron

KW - Irritable bowel syndrome

KW - Meta-analysis

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0037295146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037295146&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2982.2003.00389.x

DO - 10.1046/j.1365-2982.2003.00389.x

M3 - Article

C2 - 12588472

AN - SCOPUS:0037295146

VL - 15

SP - 79

EP - 86

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 1

ER -